NICE recommends capivasertib for advanced breast cancer

The National Institute for Health and Care Excellence (NICE) has recommended a new combination treatment for locally advanced or metastatic hormone receptor (HR)-positive, HER 2-negative breast cancer for use on the NHS in England and Wales. In final draft guidance, published on 11 April 2025, NICE approved capivasertib (Truqap; AstraZeneca), a twice-daily pill taken in […]

Publication Details

Journal: Pharmaceutical journal/The pharmaceutical journal
Published: 2025-01-01
DOI: https://doi.org/10.1211/pj.2025.1.353382
Primary Topic: Advanced Breast Cancer Therapies
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

NICE recommends capivasertib for advanced breast cancer

Jan 1, 2025

Pharmaceutical journal/The pharmaceutical journal

Advanced Breast Cancer Therapies

article

NICE recommends capivasertib for advanced breast cancer

January 1, 2025article en

Abstract

Pharmaceutical journal/The pharmaceutical journal

Openalex Percentile: Top 88%

Advanced Breast Cancer Therapies

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

NICE recommends capivasertib for advanced breast cancer · Pharmaceutical journal/The pharmaceutical journal (2025) | TGRS Research Map | TGRS